Skip to main content

Board of directors

 

Thomas Eklund

Born 1967. Member since 2015. Thomas Eklund has extensive experiences from the pharmaceutical where he has had leading positions as CEO & Head of Europe in Investor Growth Capital AB. He has also been Investment Director in Alfred Berg ABN AMRO Capital Investment AB and Vice President in Handelsbanken Markets. He is Chairman of the board of Caliditas Theraputics AB, Itrim Holdings AB, Biotage AB and Sedana Medical AB and board member of Boule Diagnostics AB, Biotage AB, Neoventa Medical AB, Memira Holdings AB, Rodebjer Form AB, Eklund konsulting AB, Surgical Science Sweden AB, Swedcare AB, Excillum AB, SciBase Holding AB, Impilo No4 Holding II AB och Tedcap.

Shareholding: 99 996 shares. Independent in relation to the company and the owners.

 

Sara Brandt

Born 1963. Member since 2017. Sara Brandt has extensive experience from marketing and sales of FMCG and Healthcare products. She has held executive positions at Unilever (Nordic), Coca-Cola (Sweden) and Cederroth/Orkla (Nordic). Sara Brandt has been the Managing Director Sweden and VP Nordic for Berner, a B2B company within the Construction and Automotive industry and is now external VP at ALMI Business Partner. She was formerly a Board member of the Association of Swedish Advertisers, Gärdin & Pärsson, DLF and KTF and is currently Chairman of Toxintelligence and Board member of ClearOn.

 
Shareholding: 0 shares. Independent in relation to the company and the owners.

Geert Cauwenbergh, PhD.
Born 1954. Member since 2012. Dr. Cauwenbergh has extensive experiences from the pharmaceutical industry and has deep knowledge of and has focused on product development and marketing of dermatology products in Europe and the U.S. Dr. Cauwenbergh is currently Managing Partner of Phases123 LLC (U.S.), CEO and Board member of RXi Pharmaceuticals Corp (U.S) and boardmember of Cutanea Life Sciences (private-USA). In the past he has served as the Chairman and CEO of Barrier Therapeutics (U.S.) and has held leading positions at Johnson & Johnson in the U.S.

Shareholding: 0 shares. Independent in relation to the company and the owners.

 

Anna Malm Bernsten

Born 1961. Member since 2018. Anna Malm Bernsten works as a consultant within business development and management through her own company. She is the previous group CEO and CEO of Carmeda AB, and has also had leading positions within international marketing and sales at, amongst others, Pharmacia, ASSA ABLOY and GE Healthcare. Anna Malm Bernsten is the chairman of the board for Medivir AB and Björn Axén AB, and board member at Cellavision AB, Probi AB and Pågengruppen AB. She has also had previous board assignments for, amongst others, Arcam AB, Biophausia AB, Neurovive AB and Oatly AB.

Shareholding: 0 shares. Independent in relation to the company and the owners.

Mattias Klintemar

Born 1967. Member since 2015. Mattias Klintemar represents Östersjöstiftelsen and has extensive experiences from leadership roles within the finance and technology sector, e.g.as CEO at Morphic Technologies AB, CFO at Hexaformer and senior corporate finance associate at ABG Sundal Collier and auditor at Arthur Andersen. He is Chairman of the board at Dilafor ad a board member at Oatly, Phoniro and Axelar as well as chairman of the nomination committee of Lightlab, Pharmanest and Cellimpact.

Shareholdin: 3 000 shares. Independent in relation to the company.

Andrew B. Hochman

Born 1979. Member since 2019. Andrew B. Hochman has over 16 years of experience in investments in pharmaceutical and consumer health care and is currently a partner at RoundTable Healthcare Partners, where he is involved in all parts of the transaction process, including deal sourcing, transaction structuring, valuation, due diligence, negotiations, financing and business strategy implementation. He joined RoundTable in 2007 from Graceway Pharmaceuticals, where he worked as Vice President of Business Development, and before that he was an associate at GTCR Golder Rauner and an analyst at William Blair & Company. He holds a Bachelor of Science degree in economics from Wharton School and a Bachelor of Arts in Psychology from the University of Pennsylvania. He is a board member of Santa Cruz Nutritionals, Revision Skincare / Goodier Cosmetics, Deerland Probiotics & Enzymes and Advantice Health, and has previously been a board member of Aqua Pharmaceuticals.

Shareholdin: 0 shares. Independent in relation to the company.

 

Current shareholding is not automatically updated for the moment. Insiders no longer have obligation to report there shareholding. According to the regulatory requirements, the data shall be updated once a year.